Prognosis assessment in metastatic gastrointestinal stromal tumors treated with tyrosine kinase inhibitors based on CT-texture analysis

被引:18
作者
Ekert, Kaspar [1 ]
Hinterleitner, Clemens [2 ]
Horger, Marius [1 ]
机构
[1] Eberhard Karls Univ Tubingen, Dept Radiol Diagnost & Intervent Radiol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany
[2] Eberhard Karls Univ Tubingen, Dept Internal Med 2, Otfried Muller Str 10, D-72076 Tubingen, Germany
关键词
CT textural features; GIST; TKI therapy; Therapy monitoring; CONTRAST-ENHANCED CT; RESPONSE EVALUATION; HETEROGENEITY; MANAGEMENT; CARCINOMA; PET;
D O I
10.1016/j.ejrad.2019.04.018
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: Identification of prognostic CT-textural features in patients with gastrointestinal stromal tumors undergoing tyrosine kinase inhibitor (TKI) therapy. Methods and materials: We identified 25 GIST patients (mean age, 70.58 +/- 9.7 years; range, 41.25-84.08 years; 20 males, 5 females) with a total of 123 scans, each examined with a standardized CT protocol between 1/2014 - 7/2018. 92 texture features, based on pyradiomics library, were extracted and correlated to response categories; evaluated with help of modified Choi criteria. All patients underwent therapy with imatinib in the first line and different tyrosine kinase inhibitors after disease progression. KIT and PDGFR-mutations were registered in all patients as well as the number of previous treatment regimens, patient's age as well as gender and the presence of contrast enhancement (vitality) in tumor. The lesion with the largest diameter was chosen and contoured using the spherical VOI tool. Inter-rater testing was performed by a second experienced radiologist. Regression and AUC analysis was performed. Results: Ten variables could be confirmed to be significantly associated with disease progression. Of them, four textural parameters were significantly positively associated with disease progression and negatively with progression free survival (Glcm Id [grey-level co-occurrence matrix inverse difference], p = 0.012, HR 3.83; 95% CI 1.697-8.611, Glcm Idn [grey-level co-occurrence matrix inverse difference normalized], p = 0.045, HR 2.06, 95% CI 1.015-4.185, Glrlm [grey-level run length matrix] normalized, p = 0.005, HR 3.181; 95% CI 1.418-7.138 and Ngtdm [neighboring grey-tone difference matrix] coarseness, p < 0.001, HR 3.156, 95% CI 1.554-6.411). Single variables were shown to be significantly inferior to the combination of all variables. After 6 months, 90% of patients with 0-1 risk factors (group 1), 64.4% with 2-3 risk variables and 38.1% of patients presenting > 3 structural risk variables showed stable disease. Gclm Id, Gclm Idn and Glrlm non-uniformity were associated with the number of previous treatments, Glrlm non-uniformity also with tumor vitality (enhancement), whereas Gclm Idn and Ngtdm coarseness were associated with the number of tumor mutations. Conclusion: Some of the CT-textural features correlate with disease progression and the progressive free survival as well as with the number of gene mutations and the number of treatment regimens the patients were exposed to as well as with the tumor enhancement. All these features reflect tumor homogeneity.
引用
收藏
页码:98 / 105
页数:8
相关论文
共 25 条
[1]  
Chacón M, 2015, FUTURE ONCOL, V11, P953, DOI [10.2217/FON.14.292, 10.2217/fon.14.292]
[2]   Role of Imaging in Response Assessment and Individualised Treatment for Sarcomas [J].
Choi, H. .
CLINICAL ONCOLOGY, 2017, 29 (08) :481-488
[3]   Response evaluation of gastrointestinal stromal tumors [J].
Choi, Haesun .
ONCOLOGIST, 2008, 13 :4-7
[4]   Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].
Choi, Haesun ;
Charnsangavej, Chuslip ;
Faria, Silvana C. ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Benjamin, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759
[5]   Imaging Modalities of Gastrointestinal Stromal Tumors [J].
Choi, Haesun .
JOURNAL OF SURGICAL ONCOLOGY, 2011, 104 (08) :907-914
[6]   Assessment of tumor heterogeneity: An emerging imaging tool for clinical practice? [J].
Davnall F. ;
Yip C.S.P. ;
Ljungqvist G. ;
Selmi M. ;
Ng F. ;
Sanghera B. ;
Ganeshan B. ;
Miles K.A. ;
Cook G.J. ;
Goh V. .
Insights into Imaging, 2012, 3 (6) :573-589
[7]   Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review [J].
Dimitrakopoulou-Strauss, Antonia ;
Ronellenfitsch, Ulrich ;
Cheng, Caixia ;
Pan, Leyun ;
Sachpekidis, Christos ;
Hohenberger, Peter ;
Henzler, Thomas .
CLINICAL AND TRANSLATIONAL IMAGING, 2017, 5 (03) :183-197
[8]   CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma - a quantitative analysis [J].
Eilaghi, Armin ;
Baig, Sameer ;
Zhang, Yucheng ;
Zhang, Junjie ;
Karanicolas, Paul ;
Gallinger, Steven ;
Khalvati, Farzad ;
Haider, Masoom A. .
BMC MEDICAL IMAGING, 2017, 17
[9]   Tumor heterogeneity in gastrointestinal stromal tumors of the small bowel: volumetric CT texture analysis as a potential biomarker for risk stratification [J].
Feng, Cui ;
Lu, Fangfang ;
Shen, Yaqi ;
Li, Anqin ;
Yu, Hao ;
Tang, Hao ;
Li, Zhen ;
Hu, Daoyu .
CANCER IMAGING, 2018, 18
[10]   CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas [J].
Ganeshan, B. ;
Miles, K. A. ;
Babikir, S. ;
Shortman, R. ;
Afaq, A. ;
Ardeshna, K. M. ;
Groves, A. M. ;
Kayani, I. .
EUROPEAN RADIOLOGY, 2017, 27 (03) :1012-1020